MCO-010 Gene Therapy Shows Promise for Retinitis Pigmentosa & GA | Healio
A new approach to treating geographic atrophy (GA), a leading cause of vision loss, is gaining traction. Researchers are exploring optogenetic therapy – a technique that uses light to restore or enhance vision – as a potential treatment, shifting the focus from simply slowing disease progression to potentially restoring lost vision. This program, utilizing MCO-010 from Nanoscope Therapeutics, is planning to launch a phase 2 trial for GA in 2026, as discussed by Theodore Leng, MD, FACS, at the Macula Society meeting.
Optogenetic Therapy: A Novel Approach to Geographic Atrophy
Geographic atrophy is a late-stage form of age-related macular degeneration (AMD) characterized by the progressive loss of retinal cells in the macula, the central part of the retina responsible for sharp, central vision. Current treatments primarily aim to slow the progression of GA, often by targeting the complement system, a part of the immune system implicated in the disease process. However, optogenetic therapy offers a fundamentally different strategy: attempting to restore visual function by making remaining retinal cells light-sensitive.
MCO-010, the optogenetic therapy under investigation, involves introducing a gene into retinal cells that encodes for a light-sensitive protein. This allows the cells to respond to light even if the natural photoreceptors are damaged or lost. Early results from studies on retinitis pigmentosa, another degenerative retinal disease, have shown promising signs of vision improvement, prompting the exploration of MCO-010 for GA. Details of the three-year data from the RESTORE and REMAIN studies were presented at the Macula Society meeting, demonstrating durable efficacy and safety in retinitis pigmentosa patients.
Who is Affected by Geographic Atrophy?
Geographic atrophy primarily affects older adults, with the prevalence increasing with age. It’s estimated that millions worldwide are affected by AMD, and a significant proportion of those with AMD will develop GA. The condition can significantly impact quality of life, making it difficult to read, drive, and recognize faces. While there is currently no cure for GA, treatments aimed at slowing its progression can help preserve vision for a longer period. The National Eye Institute provides comprehensive information on age-related macular degeneration and its various forms.
Understanding the Evidence and Limitations
The potential of optogenetic therapy for GA is based on the success seen in retinitis pigmentosa trials. However, it’s crucial to understand that GA and retinitis pigmentosa are distinct diseases with different underlying mechanisms. While the principle of restoring light sensitivity may be applicable to both, the effectiveness of MCO-010 in GA patients remains to be determined. The upcoming phase 2 trial will be critical in evaluating the safety and efficacy of this approach in a GA population.
The study presented at the Macula Society meeting, by Kay CN, et al., involved a multivariate analysis of data from the RESTORE and REMAIN trials. The findings suggest that MCO-010 can lead to vision improvement in some patients with retinitis pigmentosa, but further research is needed to understand which patients are most likely to benefit and to optimize the treatment protocol. It’s important to note that the study’s findings are specific to the patient population studied and may not be generalizable to all individuals with retinitis pigmentosa or GA.
What Does This Mean for Patients?
The development of optogenetic therapies like MCO-010 represents a significant shift in the treatment paradigm for GA. Instead of solely focusing on slowing down vision loss, researchers are now exploring ways to potentially restore lost vision. While still in the early stages of development, this approach offers hope for patients who have limited treatment options. It’s important to remember that this is an evolving field, and the availability of these therapies may be several years away.
The Public Health Process and Next Steps
The progression of MCO-010 from early-stage research to a planned phase 2 trial highlights the rigorous process of drug development. Following the phase 2 trial, if the results are promising, larger phase 3 trials will be necessary to confirm the efficacy and safety of the therapy. These trials will involve a greater number of patients and will be conducted at multiple sites. If the phase 3 trials are successful, Nanoscope Therapeutics will seek approval from regulatory agencies, such as the Food and Drug Administration (FDA) in the United States, before the therapy can be made available to the public. The FDA provides information on gene therapy products and the approval process.
Leng reports receiving grants from Astellas and Luxa Biotechnology and consulting for Apellis Pharmaceuticals, Astellas, Boehringer Ingelheim, Roche/Genentech, Toku, Topcon, Verana Health and Virtual Field. These disclosures are important to consider when evaluating the research findings, as they may represent potential conflicts of interest.
As research continues, it will be crucial to monitor the progress of clinical trials and to stay informed about the latest developments in the field of optogenetic therapy. Patients with GA should discuss their treatment options with their ophthalmologist and consider participating in clinical trials if they are eligible. The Macula Society provides resources for patients and healthcare professionals interested in learning more about macular diseases.